Recently Viewed
empty-cart

There are no Recent Items

Close
Login/Register

Close
Single User License Price USD 4995
Single User License Price INR 355744
Corporate User License Price USD 14985
Corporate User License Price INR 1067232
Site License Price USD 9990
Site License Price INR 711488
Request a Quote

Report Title

Global Orphan and Rare Dermatology Drugs Market to 2024 - An Increasingly Competitive Landscape as New Companies Enter the Market with Novel Products, Driving Strong Market Growth

Quote Request for License Type
License Type Price  
Single User License USD 4995
Site License USD 9990
Enterprise Wide License USD 14985
"Thanks for submitting the form. Our marketing team will connect back to you for the budget constraint."
Close
REQUEST A CUSTOMIZED RESEARCH

Report Title

Global Orphan and Rare Dermatology Drugs Market to 2024 - An Increasingly Competitive Landscape as New Companies Enter the Market with Novel Products, Driving Strong Market Growth


Quote Request for License Type
License Type Price  
Single User License USD 4995
"Thanks for letting us know your requirement. Our research team will connect back to you for the bespoke requirement."
Close
REQUEST FOR SAMPLE REPORT

Report Title

Global Orphan and Rare Dermatology Drugs Market to 2024 - An Increasingly Competitive Landscape as New Companies Enter the Market with Novel Products, Driving Strong Market Growth

"Thanks for submitting the form. The concerned team will send the sample report in the next 12 hours."
"Thank you for downloading the sample report."
Close

Global Orphan and Rare Dermatology Drugs Market to 2024 - An Increasingly Competitive Landscape as New Companies Enter the Market with Novel Products, Driving Strong Market Growth



Executive Summary

Global Orphan and Rare Dermatology Drugs Market to 2024 - An Increasingly Competitive Landscape as New Companies Enter the Market with Novel Products, Driving Strong Market Growth

Summary

Dermatology is a highly diverse therapy area, in terms of severity and clinical presentation, which deals with diseases of the skin, hair and nails. Whilst an orphan disease is a disease that is neglected in terms of research and funding and in the US, a disease is considered to be rare if it affects fewer than 200,000 people.

Many orphan and rare dermatology disorders are associated with significant quality of life impairments, particularly if the disease is insufficiently controlled. In particular, disease visibility can have a profoundly negative impact on patient confidence. However, the current therapeutics market is a highly genericized therapy area and there exists a significant unmet need for more efficacious and safer treatment options that treat the underlying causes of disease as opposed to managing the symptoms.

This report covers all orphan and rare dermatology disorders, but there is a particular focus on six key diseases, systemic sclerosis (scleroderma), alopecia, epidermolysis bullosa, pemphigus vulgaris, vitiligo and cutaneous lupus erythematosus, as these conditions have the largest pipelines within the therapy area.

The premium product market size for orphan and rare dermatology therapeutics was valued at USD 1.64 billion in 2017 and it is expected to grow at a compound annual growth rate (CAGR) of 20.5% to USD 6.07 billion in 2024.

Scope

- The orphan and rare dermatology market landscape is expected to change and grow. Novel targets are expected to enter the market and drive market growth with a move towards disease modifying drugs instead of drugs which manage symptoms.

- Overall, there are 262 orphan and rare dermatology products in the pipeline.

- Which molecular targets are most prominent within the pipeline?

- How do the key indications differ in terms of molecule type?

- How does the composition of the pipeline compare with that of the existing market?

- What mechanisms of action are most common for pipeline drugs?

- The premium products market size for orphan and rare dermatology therapeutics is expected to grow, from USD 1.64 billion in 2017 to USD 6.07 billion in 2024, at a CAGR of 20.5%.

- Which products will contribute to market growth most, and will any achieve blockbuster status?

- Will the current market leaders retain their dominance over the forecast period, and how is their revenue share of the orphan and rare dermatology market set to change?

- What CAGR will these companies register in the forecast period?

- How many strategic consolidations have been completed in the past decade?

- Which types of assets attract the largest deal values?

Reasons to buy

- Understand the current clinical and commercial landscape by considering disease pathogenesis, diagnosis, prognosis and the treatment options available at each stage of diagnosis for the six key indications.

- Visualize the composition of the orphan and rare dermatology market overall and across each key indication, in terms of dominant molecule types and targets, highlighting the key commercial assets and players.

- Identify trends and developments, in terms of molecule type and molecular target, within the overall orphan and rare dermatology pipeline, as well as for each of the six key indications.

- Understand the growth in patient epidemiology and market revenues for the orphan and rare dermatology market globally, and across the key players and product types.

- Consider market opportunities and potential risks by examining the incentives and challenges of drug development within the orphan market space and the trends in clinical trial duration and size, as well as clinical trial failure rates, by stage of development, molecule type and molecular target.

- Recognize how the evolving treatment landscape will drive market growth to 2024 and understand the contributions that different products, molecular targets and companies will make to this growth.

- Identify commercial opportunities in the orphan and rare dermatology deals landscape by analyzing trends in licensing and co-development deals.

1 Table of Contents

1 Table of Contents 5

1.1 List of Tables 8

1.2 List of Figures 8

2 Introduction 11

2.1 Therapy Area Overview 11

2.1.1 Overview of the Dermatology Market 11

2.1.2 Overview of Orphan and Rare Diseases 11

2.1.3 Overview of Orphan and Rare Dermatological Diseases 12

2.2 Symptoms 14

2.3 Diagnosis 16

2.3.1 Systemic Sclerosis 17

2.3.2 Alopecia 17

2.3.3 Epidermolysis Bullosa 18

2.3.4 Pemphigus Vulgaris 18

2.3.5 Vitiligo 19

2.3.6 Cutaneous Lupus Erythematosus 19

2.4 Etiology 20

2.5 Pathophysiology 21

2.5.1 Systemic sclerosis 21

2.5.2 Alopecia 22

2.5.3 Epidermolysis Bullosa 23

2.5.4 Pemphigus Vulgaris 23

2.5.5 Vitiligo 23

2.5.6 Cutaneous Lupus Erythematosus 24

2.6 Epidemiology 25

2.6.1 Systemic sclerosis 25

2.6.2 Alopecia 26

2.6.3 Epidermolysis Bullosa 26

2.6.4 Pemphigus Vulgaris 26

2.6.5 Vitiligo 27

2.6.6 Cutaneous Lupus Erythematosus 27

2.7 Co-morbidities and Complications 27

2.7.1 Systemic sclerosis 27

2.7.2 Alopecia 28

2.7.3 Epidermolysis Bullosa 28

2.7.4 Pemphigus Vulgaris 28

2.7.5 Vitiligo 29

2.7.6 Cutaneous Lupus Erythematosus 29

2.8 Prognosis 29

2.8.1 Systemic Sclerosis 29

2.8.2 Alopecia 29

2.8.3 Epidermolysis Bullosa 30

2.8.4 Pemphigus Vulgaris 30

2.8.5 Vitiligo 30

2.8.6 Cutaneous Lupus Erythematosus 31

2.9 Treatment 31

2.9.1 Systemic Sclerosis 32

2.9.2 Alopecia 32

2.9.3 Epidermolysis Bullosa 33

2.9.4 Pemphigus Vulgaris 33

2.9.5 Vitiligo 34

2.9.6 Cutaneous Lupus Erythematosus 34

3 Key Marketed Products 36

3.1 Overview 36

3.2 Premium Drugs 38

3.2.1 Humira (adalimumab) - AbbVie 38

3.2.2 Ilaris (canakinumab) - Novartis 40

3.2.3 Afinitor (everolimus) - Novartis 41

3.2.4 Kineret (anakinra) - Swedish Orphan Biovitrum 43

3.2.5 Arcalyst (rilonacept) - Regeneron Pharmaceuticals 45

3.2.6 Tracleer (bosentan) - Johnson & Johnson 47

3.2.7 Thalomid (thalidomide) - Celgene 49

3.3 Highly Genericized Drugs 53

3.3.1 Medrol (methylprednisolone) - Pfizer 53

3.3.2 Meticorten/Rayos (Prednisone) - Merck & Co./Horizon Pharma 55

4 Pipeline Landscape Assessment 58

4.1 Overview 58

4.2 Pipeline by Stage of Development, Molecule Type and Program Type 59

4.2.1 Overall Pipeline 59

4.2.2 Pipeline by Key Indication 60

4.3 Molecular Targets in the Pipeline 63

4.3.1 Overall Pipeline 63

4.3.2 Pipeline by Key Indication 64

4.4 Clinical Trials Landscape 65

4.4.1 Challenges Associated with Clinical Trials for Orphan and Rare Diseases 66

4.4.2 Incentives for Clinical Trials for Orphan and Rare Diseases 67

4.4.3 Clinical Trial Failure Rates 68

4.4.4 Clinical Trial Duration 69

4.4.5 Clinical Trial Size 70

4.4.6 Cumulative Clinical Trial Size 70

4.5 Assessment of Key Pipeline Products 71

4.5.1 Epidiolex (cannabidiol) - GW Pharmaceuticals 72

4.5.2 Episalvan (birch bark extract) - Amryt Pharma 73

4.5.3 KB-103 - Krystal Biotech 74

4.5.4 Givosiran - Alnylam Pharmaceuticals 75

4.5.5 EB-101 - Abeona Therapeutics 77

4.5.6 OTL-103 - Orchard Therapeutics 78

4.5.7 Siponimod - Novartis 79

4.5.8 FCX-007 - Fibrocell Science 80

5 Multi-scenario Market Forecast to 2024 82

5.1 Market Size 82

5.2 Revenue Forecast by Molecular Target 85

5.2.1 Products Acting on Interleukins 85

5.2.2 Products Acting on Tumor Necrosis Factor-Alpha 86

5.2.3 Products Acting on Tyrosine Protein Kinases 87

5.2.4 Products Acting on Hormones and Hormone Receptors 88

6 Company Analysis and Positioning 90

6.1 Revenue and Market Share Analysis by Company 92

6.1.1 Novartis 98

6.1.2 GW Pharmaceuticals 99

6.1.3 AbbVie 100

6.1.4 Roche 101

6.1.5 Pfizer 101

6.1.6 Amryt Pharma 103

6.1.7 GlaxoSmithKline 104

6.1.8 Celgene 105

6.2 Company Landscape 106

6.3 Marketed and Pipeline Portfolio Analysis 107

7 Strategic Consolidations 109

7.1 Licensing Deals 109

7.1.1 Deals by Region, Year and Value 109

7.1.2 Deals by Key Indication and Value 111

7.1.3 Deals by Stage of Development and Value 112

7.1.4 Deals by Molecule Type, Molecular Target and Value 113

7.1.5 Licensing Deals with Disclosed Values 114

7.2 Co-development Deals 115

7.2.1 Deals by Region, Year and Value 115

7.2.2 Deals by Key Indication and Value 116

7.2.3 Deals by Stage of Development and Value 117

7.2.4 Deals by Molecule Type, Molecular Target and Value 118

7.2.5 Co-development Deals with Disclosed Values 119

8 Appendix 120

8.1 References 120

8.2 Figures of All Pipeline Products 129

8.3 Abbreviations 136

8.4 Disease List 137

8.5 Methodology 137

8.5.1 Coverage 137

8.5.2 Secondary Research 138

8.5.3 Market Size and Revenue Forecasts 138

8.5.4 Pipeline Analysis 138

8.5.5 Competitive Landscape 139

8.6 Contact Us 139

8.7 Disclaimer 139

To know more information on Purchase by Section, please send a mail to sales@kenresearch.com

1.2 List of Figures

Figure 1: Orphan and Rare Dermatology Drugs Market, 7MM, Epidemiology Patterns for Systemic Sclerosis (Scleroderma), 2017-2024 26

Figure 2: Orphan and Rare Dermatology Drugs Market, Global, Annual Revenue for Humira (USD bn), 2006-2024 39

Figure 3: Orphan and Rare Dermatology Drugs Market, Global, Annual Revenue for Ilaris (USD bn), 2009-2024 41

Figure 4: Orphan and Rare Dermatology Drugs Market, Global, Annual Revenue for Afinitor (USD bn), 2008-2024 43

Figure 5: Orphan and Rare Dermatology Drugs Market, Global, Annual Revenue for Kineret (USD m), 2008-2024 45

Figure 6: Orphan and Rare Dermatology Drugs Market, Global, Annual Revenue for Arcalyst (USD m), 2008-2024 47

Figure 7: Orphan and Rare Dermatology Drugs Market, Global, Annual Revenue for Tracleer (USD bn), 2006-2024 49

Figure 8: Orphan and Rare Dermatology Drugs Market, Global, Annual Revenue for Thalomid (USD m), 2006-2024 52

Figure 9: Orphan and Rare Dermatology Drugs Market, Global, Annual Revenue for Medrol (USD m), 2008-2024 55

Figure 10: Orphan and Rare Dermatology Drugs Market, US, Annual Revenue for Rayos (USD bn), 2013-2024 57

Figure 11: Orphan and Rare Dermatology Drugs Market, Global, Overall Pharmaceutical Industry Pipeline by Therapy Area, 2018 58

Figure 12: Orphan and Rare Dermatology Drugs Market, Global, Overall Pipeline by Stage of Development, Molecule Type and Program Type, 2018 60

Figure 13: Orphan and Rare Dermatology Drugs Market, Global, Pipeline for Key Indications by Stage of Development, 2018 61

Figure 14: Orphan and Rare Dermatology Drugs Market, Global, Pipeline for Key Indications by Molecule Type, 2018 62

Figure 15: Orphan and Rare Dermatology Drugs Market, Global, Overall Pipeline by Molecular Target and Stage of Development, 2018 64

Figure 16: Orphan and Rare Dermatology Drugs Market, Global, Pipeline for Key Indications by Molecular Target, 2018 65

Figure 17: Orphan and Rare Dermatology Drugs Market, Global, Clinical Trial Attrition Rates by Stage of Development (%), 2006-2018 69

Figure 18: Orphan and Rare Dermatology Drugs Market, Global, Clinical Trial Duration by Stage of Development (months), 2006-2018 69

Figure 19: Orphan and Rare Dermatology Drugs Market, Global, Clinical Trial Size by Stage of Development (participants), 2006-2018 70

Figure 20: Orphan and Rare Dermatology Drugs Market, Global, Clinical Program Size by Stage of Development (participants), 2006-2018 71

Figure 21: Orphan and Rare Dermatology Drugs Market, Global, Revenue Forecast for Epidiolex (USD m), 2019-2024 73

Figure 22: Orphan and Rare Dermatology Drugs Market, Global, Revenue Forecast for Episalvan (birch bark extract) (USD m), 2020-2024 74

Figure 23: Orphan and Rare Dermatology Drugs Market, Global, Revenue Forecast for KB-103 (USD m), 2021-2024 75

Figure 24: Orphan and Rare Dermatology Drugs Market, Global, Revenue Forecast for Givosiran (USD m), 2019-2024 76

Figure 25: Orphan and Rare Dermatology Drugs Market, Global, Revenue Forecast for EB-101 (USD m), 2020-2024 78

Figure 26: Orphan and Rare Dermatology Drugs Market, Global, Revenue Forecast for OTL-103 (USD m), 2021-2024 79

Figure 27: Orphan and Rare Dermatology Drugs Market, Global, Revenue Forecast for Siponimod (USD m), 2021-2024 80

Figure 28: Orphan and Rare Dermatology Drugs Market, Global, Revenue Forecast for FCX-007 (USD m), 2021-2024 81

Figure 29: Orphan and Rare Dermatology Drugs Market, Global, Premium Product Market Size (USD bn), 2017-2024 83

Figure 30: Orphan and Rare Dermatology Drugs Market, Global, Annual Revenue Forecast for Products Acting on Interleukins (USD m), 2017-2024 86

Figure 31: Orphan and Rare Dermatology Drugs Market, Global, Annual Revenue Forecast for Products Acting on TNF-? (USD m), 2017-2024 87

Figure 32: Orphan and Rare Dermatology Drugs Market, Global, Annual Revenue Forecast for Products Acting on Tyrosine Protein Kinases (USD m), 2019-2024 88

Figure 33: Orphan and Rare Dermatology Drugs Market, Global, Annual Revenue Forecast for Products Acting on Hormones and Receptors (USD m), 2017-2024 89

Figure 34: Orphan and Rare Dermatology Drugs Market, Global, Company Analysis Matrix, 2017-2024 90

Figure 35: Orphan and Rare Dermatology Drugs Market, Global, Cluster by CAGR and Market Share, 2017-2024 91

Figure 36: Orphan and Rare Dermatology Drugs Market, Global, Forecast Market Share by Company (%), 2017-2024 95

Figure 37: Orphan and Rare Dermatology Drugs Market, Global, Companies by Compound Annual Growth Rate (%), 2017-2024 96

Figure 38: Orphan and Rare Dermatology Drugs Market, Global, Revenues by Route of Acquisition, 2017-2024 97

Figure 39: Orphan and Rare Dermatology Drugs Market, Global, Novartis Orphan and Rare Dermatology Annual Revenue Forecast (USD m), 2017-2024 98

Figure 40: Orphan and Rare Dermatology Drugs Market, Global, GW Pharmaceuticals Orphan and Rare Dermatology Annual Revenue Forecast (USD m), 2017-2024 99

Figure 41: Orphan and Rare Dermatology Drugs Market, Global, AbbVie Orphan and Rare Dermatology Annual Revenue Forecast (USD m), 2017-2024 100

Figure 42: Orphan Dermatology Drugs Market, Global, Roche Orphan and Rare Dermatology Annual Revenue Forecast (USD m), 2018-2024 101

Figure 43: Orphan and Rare Dermatology Drugs Market, Global, Pfizer Orphan and Rare Dermatology Annual Revenue Forecast (USD m), 2017-2024 102

Figure 44: Orphan and Rare Dermatology Drugs Market, Global, Amryt Orphan and Rare Dermatology Annual Revenue Forecast (USD m), 2017-2024 103

Figure 45: Orphan and Rare Dermatology Drugs Market, Global, GlaxoSmithKline Orphan and Rare Dermatology Annual Revenue Forecast (USD m), 2018-2024 104

Figure 46: Orphan and Rare Dermatology Drugs Market, Global, Celgene Orphan and Rare Dermatology Annual Revenue Forecast (USD m), 2017-2024 105

Figure 47: Orphan and Rare Dermatology Drugs Market, Global, Late-Stage Pipeline Developers by Type, 2018 106

Figure 48: Orphan and Rare Dermatology Drugs Market, Global, Pipeline and Late-Stage Developers by Level of Orphan and Rare Dermatology Specialization, 2018 107

Figure 49: Orphan and Rare Dermatology Drugs Market, Global, Proportion of Total Company Revenue Attributed to Orphan and Rare Dermatology, 2024 108

Figure 50: Orphan and Rare Dermatology Drugs Market, Global, Licensing Deals by Region, Value and Year, 2006-2018 110

Figure 51: Orphan and Rare Dermatology Drugs Market, Global, Licensing Deals by Indication, 2006-2018 111

Figure 52: Orphan and Rare Dermatology Drugs Market, Global, Licensing Deals by Stage of Development and Value, 2006-2018 112

Figure 53: Orphan and Rare Dermatology Drugs Market, Global, Licensing Deals by Molecule Type and Molecular Target, 2006-2018 113

Figure 54: Orphan and Rare Dermatology Drugs Market, Global, Licensing Deals with Disclosed Values, 2006-2018 114

Figure 55: Orphan and Rare Dermatology Drugs Market, Global, Co-development Deals by Region, Year and Value, 2006-2018 115

Figure 56: Orphan and Rare Dermatology Drugs Market, Global, Co-development Deals by Key Indication, 2006-2018 116

Figure 57: Orphan and Rare Dermatology Drugs Market, Global, Co-development Deals by Stage of Development and Value, 2006-2018 117

Figure 58: Orphan and Rare Dermatology Drugs Market, Global, Co-development Deals by Molecule Type and Molecular Target, 2006-2018 118

Figure 59: Orphan and Rare Dermatology Drugs Market, Global, Co-development Deals with Disclosed Values, 2006-2018 119

Figure 60: Orphan and Rare Dermatology Drugs Market, Global, All Pipeline Products, 2018 (part 1) 129

1.1 List of Tables

Table 1: Orphan and Rare Dermatology Drugs Market, Global, Symptoms of the Key Indications, 2018 15

Table 2: Orphan and Rare Dermatology Drugs Market, Global, Etiology of the Key Indications, 2018 20

Table 3: Orphan and Rare Dermatology Drugs Market, Global, Prognosis for Epidermolysis Bullosa, 2018 30

Table 4: Orphan and Rare Dermatology Drugs Market, Global, Key Marketed Products and Approved Indications, 2018 37

Table 5: Orphan and Rare Dermatology Drugs Market, Global, Approved Orphan and Rare Dermatology Indications for Humira, 2018 38

Table 6: Orphan and Rare Dermatology Drugs Market, Global, Approved Orphan and Rare Dermatology Indications for Ilaris, 2018 40

Table 7: Orphan and Rare Dermatology Drugs Market, Global, Approved Orphan and Rare Dermatology Indications for Afinitor, 2018 42

Table 8: Orphan and Rare Dermatology Drugs Market, Global, Approved Orphan and Rare Dermatology Indications for Kineret, 2018 44

Table 9: Orphan and Rare Dermatology Drugs Market, Global, Approved Orphan and Rare Dermatology Indications for Arcalyst, 2018 46

Table 10: Orphan and Rare Dermatology Drugs Market, Global, Approved Orphan and Rare Dermatology Indications for Tracleer, 2018 48

Table 11: Orphan and Rare Dermatology Drugs Market, Global, Approved Orphan and Rare Dermatology Indications for Thalomid, 2018 50

Table 12: Orphan and Rare Dermatology Drugs Market, Global, Approved Orphan and Rare Dermatology Indications for Methylprednisolone, 2018 54

Table 13: Orphan and Rare Dermatology Drugs Market, Global, Approved Orphan and Rare Dermatology Indications for Meticorten, 2018 56

Table 14: Orphan and Rare Dermatology Drugs Market, US, Approved Orphan and Rare Dermatology Indications for Rayos, 2018 56

Table 15: Orphan and Rare Dermatology Drugs Market, Global, Annual Revenue Forecast for Key Products (USD m), 2017-2024 84

Table 16: Orphan and Rare Dermatology Drugs Market, Global, Forecast Revenue by Company (%), 2017-2024 93

Single User License:
Report can be used by individual purchaser only

Site License:
Report can be shared by unlimited users within one corporate location, e.g. a regional office

Corporate User License:
Report can be shared globally by unlimited users within the purchasing corporation e.g. all employees of a single company


Related Products in vertical
red-whiteline

RECENT VIEWED REPORTS



Sign up for newsletter

Close
Apply For Job

  • Applicant Name
  • Job Function
  • Total Experience
  • Skills
  • Email ID
  • Notice Period
  • Current CTC & Expected CTC
  • Phone Number
  • Validation
  • captcha  info-icon

    If validation code does not match, please refresh the page.

  • "Your resume has been successfully received. HR will connect you within 14 days in case your resume gets shortlisted."
Close
Download Company Brochure

  • Name
  • Email
  • Company Name
  • Select Country*
  • Phone Number
  • Validation
  •   info-icon

    If validation code does not match, please refresh the page.

Close
Engage With Us

  • Name
  • Designation
  • Email
  • Phone No.
  • Company Name
  • Company URL
  • Select Country*
  • Requirements/ Comments
  • Validation
  • captcha  info-icon

    If validation code does not match, please refresh the page.

  • "Thanks for submitting the form. The concerned team will respond to your query in the next 8-12 hours"
Close

Compare

Expand

person